RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Clinical trials for RECURRENT SMALL LYMPHOCYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT SMALL LYMPHOCYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT SMALL LYMPHOCYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Double-Target CAR-T cells tested in fight against tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy designed to attack two common proteins (CD19 and CD20) found on certain blood cancer cells. The therapy involves collecting a patient's own immune cells, modifying them in a lab to reco…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Scientists re-engineer Patient's own cells to hunt down blood cancers
Disease control OngoingThis early-stage study is testing a new type of cellular immunotherapy for adults whose B-cell lymphoma or leukemia has come back. Doctors collect a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer cells, and then infuse them back…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Double-Drug attack on blood cancer shows promise
Disease control OngoingThis study tests whether taking two oral medications together—venetoclax and ibrutinib—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is for adults whose cancer has returned after prior treatment or who have high-risk, untreated dis…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New dosing strategy aims to tame blood cancer with fewer side effects
Disease control OngoingThis study is testing whether giving the cancer drug duvelisib on an irregular schedule works as well as continuous dosing but with fewer severe side effects. It is for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding …
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Engineered immune cells target cancer in groundbreaking lymphoma trial
Disease control OngoingThis early-phase study is testing a new type of cell therapy for patients with high-risk or returning B-cell non-Hodgkin lymphoma. After receiving a stem cell transplant, patients get an infusion of their own immune cells that have been genetically modified in a lab to better fin…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Early trial tests Triple-Threat attack on stubborn blood cancers
Disease control OngoingThis early-phase study is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The main goals are to find t…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
Cancer trial tests drug combo to keep leukemia at bay
Disease control OngoingThis study aims to find out if adding the immunotherapy drug rituximab to the cancer drug ibrutinib works better than ibrutinib alone for adults whose chronic lymphocytic leukemia has returned after prior treatment. It will compare how long patients stay cancer-free on each regim…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive lymphoma
Disease control OngoingThis study is testing a new type of personalized cell therapy for patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to better tar…
Matched conditions: RECURRENT SMALL LYMPHOCYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 05, 2026 13:59 UTC